These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 10414837)

  • 1. Production gains from health care: what should be included in cost-effectiveness analyses?
    Olsen JA; Richardson J
    Soc Sci Med; 1999 Jul; 49(1):17-26. PubMed ID: 10414837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The friction cost method: a comment.
    Johannesson M; Karlsson G
    J Health Econ; 1997 Apr; 16(2):249-55; discussion 257-9. PubMed ID: 10173080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The potential to forgo social welfare gains through overrelianceon cost effectiveness/cost utility analyses in the evidence base for public health.
    Cohen DR; Patel N
    J Environ Public Health; 2009; 2009():107927. PubMed ID: 20049165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Productivity costs in cost-effectiveness analysis: numerator or denominator: a further discussion.
    Brouwer WB; Koopmanschap MA; Rutten FF
    Health Econ; 1997; 6(5):511-4. PubMed ID: 9353652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Towards a new approach for estimating indirect costs of disease.
    Koopmanschap MA; van Ineveld BM
    Soc Sci Med; 1992 May; 34(9):1005-10. PubMed ID: 1631600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Measurement of indirect costs for people with vision impairment.
    Chou SL; Misajon R; Gallo J; Keeffe JE
    Clin Exp Ophthalmol; 2003 Aug; 31(4):336-40. PubMed ID: 12880460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health.
    Griebsch I; Coast J; Brown J
    Pediatrics; 2005 May; 115(5):e600-14. PubMed ID: 15867026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimating the Societal Benefits of THA After Accounting for Work Status and Productivity: A Markov Model Approach.
    Koenig L; Zhang Q; Austin MS; Demiralp B; Fehring TK; Feng C; Mather RC; Nguyen JT; Saavoss A; Springer BD; Yates AJ
    Clin Orthop Relat Res; 2016 Dec; 474(12):2645-2654. PubMed ID: 27699631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Friction-cost method as an alternative to the human-capital approach in calculating indirect costs.
    Birnbaum H
    Pharmacoeconomics; 2005; 23(2):103-4. PubMed ID: 15748084
    [No Abstract]   [Full Text] [Related]  

  • 10. Systematic review and quality assessment of economic evaluations and quality-of-life studies related to generalized anxiety disorder.
    Bereza BG; Machado M; Einarson TR
    Clin Ther; 2009 Jun; 31(6):1279-308. PubMed ID: 19695395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic analysis in dermatology.
    Ellis CN; Reiter KL; Wheeler JR; Fendrick AM
    J Am Acad Dermatol; 2002 Feb; 46(2):271-83. PubMed ID: 11807441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analytic approaches for the evaluation of costs.
    Glick HA; Polsky D
    Hepatology; 1999 Jun; 29(6 Suppl):18S-22S. PubMed ID: 10386078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The friction-cost method : replacement for nothing and leisure for free?
    Brouwer WB; Koopmanschap MA
    Pharmacoeconomics; 2005; 23(2):105-11. PubMed ID: 15748085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Productivity costs, time costs and health-related quality of life: a response to the Erasmus Group.
    Weinstein MC; Siegel JE; Garber AM; Lipscomb J; Luce BR; Manning WG; Torrance GW
    Health Econ; 1997; 6(5):505-10. PubMed ID: 9353651
    [No Abstract]   [Full Text] [Related]  

  • 15. Using cost-effectiveness/cost-benefit analysis to allocate health resources: a level playing field for prevention?
    Phillips KA; Hotlgrave DR
    Am J Prev Med; 1997; 13(1):18-25. PubMed ID: 9037338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Costs of illness in cost-effectiveness analysis. A review of the methodology.
    Hodgson TA
    Pharmacoeconomics; 1994 Dec; 6(6):536-52. PubMed ID: 10155283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating the cost-effectiveness of clinical and public health measures.
    Graham JD; Corso PS; Morris JM; Segui-Gomez M; Weinstein MC
    Annu Rev Public Health; 1998; 19():125-52. PubMed ID: 9611615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Accounting for the missing opportunity costs in incremental cost-outcome analysis.
    Oliver A
    Appl Health Econ Health Policy; 2002; 1(4):191-6. PubMed ID: 14619248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Indirect cost in economic evaluation: the opportunity cost of unpaid inputs.
    Posnett J; Jan S
    Health Econ; 1996; 5(1):13-23. PubMed ID: 8653189
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.